Research programme: helix-based peptide therapeutics - Prism
Latest Information Update: 26 Jul 2011
Price :
$50 *
At a glance
- Originator Commonwealth Biotechnologies
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 26 Jul 2011 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 12 May 2011 Prism Pharmaceuticals has been acquired by Baxter International
- 02 Jun 2006 Preclinical trials in Cardiovascular disorders in USA (unspecified route)